3M Company vs Neurocrine Biosciences Inc — how do they compare? 3M Company trades at $170.65 (market cap $82.99B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: 3M Company is far larger — about 4.8× Neurocrine Biosciences Inc's market cap, and 3M Company pays a 1.96% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MMM | NBIX | |
|---|---|---|
Market Cap | $82.99B | $17.40B |
Sector | Industrials | Health |
52-Week High | $174.61 | $180.55 |
52-Week Low | $141.10 | $123.10 |
Enterprise Value | $91.39B | $16.49B |
Dividend Yield | 1.96% | — |
Signals from Pluang's Aura AI — not financial advice
3M (MMM) surged 6.83% to $170.76 following strong Q2 2026 earnings that beat expectations, with the company raising full-year guidance. Technical indicators show a bullish trend with support at $158 and resistance at $161. Fundamentally, the company demonstrates robust profitability with 39.71% gross margins and 72.14% ROE, though revenue has declined from 2022 peaks. Recent news highlights operational improvements and growth in Safety & Industrial and Transport & Electronics segments.
The outlook is positive with earnings momentum and raised guidance, but risks include litigation liabilities and macroeconomic headwinds. Analyst consensus is mixed with 48% buy ratings but a $149.75 price target below current levels, suggesting limited near-term upside despite strong operational performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →